))
The Economics of Ozempic & Other Weight Loss Drugs: A Deep Dive with Ben Ippolito
Manage episode 419171214 series 3439064
Content provided by DC EKG and Evergreen Podcasts | Big Whig Media. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DC EKG and Evergreen Podcasts | Big Whig Media or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Join hosts Joe Grogan and Eric Ueland on DC EKG as they delve into the complexities of health economics in America with special guest Ben Ippolito. In this episode, they explore the skyrocketing prices of GLP-1 weight loss drugs and discuss the potential for Medicare coverage. Ben Ippolito sheds light on the current prohibition against Medicare covering weight loss drugs, the shift from viewing obesity as a cosmetic issue to recognizing it as a clinical outcome, and the high out-of-pocket expenses people are willing to pay. Ben also examines the business implications for pharmaceutical companies if Medicare covers these drugs, the impact of price caps under the IRA, and the competitive challenges new market entrants face.
--LINKS--
Follow DC EKG: https://twitter.com/DCEKGpodcast
Follow Ben: https://twitter.com/ben_ippolito
81 episodes
Share
